Drug intelligence / Profile preview

SZEY-2108

Development stage: Phase 1
Lead developer: Suzhou Erye Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

SZEY-2108 is a novel monocyclic β-lactam antibiotic developed by Suzhou Erye Pharmaceutical. It is being tested for its safety and pharmacokinetics in healthy subjects via intravenous infusions. The primary indication is for treating infections, specifically carbapenem-resistant enterobacter infections.

Beyond the preview

Go deeper on SZEY-2108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SZEY-2108.

Explore the full profile